Cargando…

Psoriasis Prevalence and Severity by Expert Elicitation

INTRODUCTION: An estimated 2–4% of Western populations are thought to have psoriasis, with a regional incidence ranging from 0.09% to 11.43%. Variance in estimates is a result of differences in study populations, methodology, regional differences, and definitions of disease. Reliable prevalence esti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papp, Kim A., Gniadecki, Robert, Beecker, Jennifer, Dutz, Jan, Gooderham, Melinda J., Hong, Chih-Ho, Kirchhof, Mark G., Lynde, Chuck W., Maari, Catherine, Poulin, Yves, Vender, Ron B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163919/ https://www.ncbi.nlm.nih.gov/pubmed/33886086 http://dx.doi.org/10.1007/s13555-021-00518-8

Ejemplares similares

Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
por: Papp, Kim A., et al.
Publicado: (2021)

Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2022)

Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

35158 Adaptations in the PURE registry in response to the COVID 19 pandemic: The impact of well-designed modifications in real-world data collection in a psoriasis registry
por: Lynde, Charles, et al.
Publicado: (2022)

Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome
por: Lima, Hermenio, et al.
Publicado: (2017)

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
por: Gooderham, Melinda, et al.
Publicado: (2022)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America
por: Papp, Kim A., et al.
Publicado: (2019)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021)

Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers
por: Vender, Ronald B., et al.
Publicado: (2022)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

35181 Baseline disease and population characteristics associated with a diagnosis of COVID 19: Data from the PURE registry
por: Albrecht, Lorne, et al.
Publicado: (2022)

Management of scalp psoriasis: current perspectives
por: Blakely, Kim, et al.
Publicado: (2016)

Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic, Milica, et al.
Publicado: (2021)

Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody
por: Papp, K.A., et al.
Publicado: (2018)

Diagnosis of Generalized Pustular Psoriasis
por: Fujita, Hideki, et al.
Publicado: (2022)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE
por: Papp, K.A., et al.
Publicado: (2015)

Reverse koebnerization of primary cutaneous follicle center lymphoma following skin biopsy
por: Choi, Bohmyi, et al.
Publicado: (2021)

Return of Lymantria dispar dispar (gypsy moth): A case report
por: Haq, Mawiyah, et al.
Publicado: (2021)

Tapinarof for the treatment of psoriasis
por: Nogueira, Sofia, et al.
Publicado: (2022)

Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review
por: Papp, Kim A., et al.
Publicado: (2021)

Psoriasis, biologic therapy, and the pandemic of the 21st century
por: Nogueira, Miguel, et al.
Publicado: (2020)

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
por: Papp, KA, et al.
Publicado: (2015)

34304 Persistence and adherence to ixekizumab treatment in patients with moderate-to-severe psoriasis before and during COVID-19 pandemic: Results from the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Development and validation of a new method for potential use of Psoriasis Area and Severity Index in teledermatology
por: Wu, Jason, et al.
Publicado: (2020)

Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)
por: Lynde, Charles W., et al.
Publicado: (2022)

Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report
por: Bose, Reetesh, et al.
Publicado: (2020)

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
por: Pariser, David, et al.
Publicado: (2017)

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
por: Wu, J.J., et al.
Publicado: (2022)

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study
por: Weisel, Kathleen, et al.
Publicado: (2020)

A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians
por: Drakos, Anastasia, et al.
Publicado: (2022)

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
por: Papp, K.A., et al.
Publicado: (2017)

Eliciting and analyzing expert judgment : a practical guide /
por: Meyer, Mary A.
Publicado: (1991)

Plaque psoriasis and morphea in a patient on ustekinumab: A case report
por: Cirone, Katrina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d4b34n1gpaetgpsla2o831su3f